Results & Expectations
    Retatrutide

    Retatrutide 1-Month Results

    The first month on retatrutide is about building a foundation -- adjusting to the medication, managing early side effects, and starting to see the scale move. Here is what the data shows and what patients can realistically expect.

    Published: April 3, 202613 min read

    The first month on retatrutide sets expectations for the entire treatment journey. Patients who understand that the titration phase produces modest initial results -- and that the dramatic 24% weight loss seen in Phase 2 trials (Jastreboff et al., NEJM 2023) develops over 48 weeks, not 4 -- are more likely to stay committed through the early adjustment period and ultimately achieve their goals.

    Data Context

    Weight loss figures are estimates based on Phase 2 trial data at starting doses. Individual results vary significantly. Retatrutide is investigational and not FDA-approved.

    Week-by-Week First Month

    Month 1 Timeline

    Week 1: Adjustment

    First injection at starting dose (0.5-1mg). Mild appetite reduction begins within 2-3 days. Possible nausea, typically mild. Weight loss: 1-3 pounds (mostly water and glycogen initially).

    Week 2: Settling In

    Second injection. Appetite suppression becomes more noticeable. GI side effects may peak then begin to improve. Weight loss: 1-2 additional pounds. Drug levels approaching steady state at starting dose.

    Week 3: Finding Your Rhythm

    Third injection. Body adapting to medication. Appetite consistently reduced. Side effects typically improving. Weight loss continuing at 1-2 pounds per week. Starting to establish new eating patterns.

    Week 4: First Milestone

    Fourth injection. Steady state achieved at starting dose. Dose increase may be prescribed. Total month 1 weight loss: typically 3-6% of body weight. Clothing may begin to feel slightly looser.

    What to Focus on in Month 1

    • Protein intake: Begin establishing the habit of prioritizing protein at every meal. Target 80-120 grams daily.
    • Hydration: Drink at least 64 ounces of water daily. GLP-1 medications increase dehydration risk.
    • Exercise initiation: Start with daily walking (15-30 minutes) and introduce basic resistance training 2x per week.
    • Side effect management: Eat small, frequent meals. Avoid greasy and heavy foods. Ginger tea or ginger candies can help with nausea.
    • Mindset: Focus on the process, not the scale. The dramatic results come in months 3-12, not month 1.

    When to Contact Your Provider

    While mild side effects are normal, contact your provider if you experience persistent vomiting (unable to keep liquids down), severe abdominal pain, signs of pancreatitis (radiating abdominal pain with nausea), or inability to eat or drink for more than 24 hours.

    To get started with currently available weight loss treatments, visit our treatments page.

    Medical Disclaimer

    This article is for educational purposes only. Retatrutide is not FDA-approved. Results are estimates based on Phase 2 data (Jastreboff et al., NEJM 2023). Individual results vary. Consult a healthcare provider for treatment guidance.

    Start Your Month 1 Today

    Begin losing weight now. Semaglutide from $99/mo, tirzepatide from $125/mo.

    Get Started Today

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    What are typical retatrutide 1-month results?

    Retatrutide 1-month results from phase 2 TRIUMPH-1 trial (Jastreboff et al., NEJM 2023): minimal weight change in the first 4 weeks during the dose titration phase. Most patients lose only 2-5 lbs in the first month because they're at the starting dose (1-2 mg/week) during weeks 1-4, the medication's weight-loss effect accelerates significantly as the dose escalates over weeks 5-24. Why minimal early loss: GLP-1-class medications including retatrutide work through gradual appetite suppression and metabolic shifts; the body adapts to the medication's mechanism over time, and significant clinical effect requires reaching therapeutic dose levels (typically 8-12 mg/week for retatrutide). Initial side effects (weeks 1-4): nausea (10-20% at low doses), mild GI symptoms, these improve with dose stabilization. Realistic 1-month expectations on retatrutide: 2-5 lbs weight loss; reduced appetite (slowly building); mild GI side effects (manageable). Comparison to FDA-approved options now available: tirzepatide at proper titration (2.5 mg/week starting dose) shows ~5-7 lbs loss in first month per SURMOUNT-1 trial subgroup analyses; semaglutide (Wegovy) at 0.25 mg starting shows ~3-5 lbs loss in first month per STEP 1. Important caveat: retatrutide is investigational and NOT FDA-approved as of May 2026; expected approval 2027-2028 if phase 3 trials succeed. For weight-loss treatment now, FDA-approved tirzepatide is the closest accessible alternative, Trimi compounded tirzepatide $125/month annual via Arora Health 50-state US-licensed clinician network. Patients should NOT seek 'research peptide' retatrutide outside legitimate clinical trial enrollment. Set realistic expectations: GLP-1-class medications have a gradual weight-loss curve; significant change typically begins weeks 8-12 as dose escalates to therapeutic level. Don't be discouraged by slow initial loss, focus on tolerance and adherence during titration.

    Phase 2: 2-5 lbs weight loss in first month (titration phase).
    Loss accelerates after week 4 as dose escalates.
    Tirzepatide alternative: ~5-7 lbs first month at proper titration.

    Key Takeaways

    • Retatrutide 1-month results from phase 2 TRIUMPH-1 (NEJM 2023): minimal weight change in first 4 weeks during titration phase (most patients lose 2-5 lbs).
    • Patients are at starting dose (1-2 mg/week) during weeks 1-4; weight loss accelerates as dose escalates.
    • Initial side effects (weeks 1-4): nausea, mild GI symptoms, improve with dose stabilization.
    • Retatrutide is investigational and NOT FDA-approved; for weight loss now, FDA-approved tirzepatide (Trimi $125/mo annual) shows ~5-7 lbs loss in first month at proper titration.
    • Set realistic expectations: GLP-1-class medications have gradual weight-loss curve; significant change typically begins weeks 8-12.

    Medically Reviewed

    DMR

    Dr. Michael Rodriguez

    MD, FACP, Board Certified in Internal Medicine

    Internal Medicine & Weight Management

    Last reviewed: November 5, 2025

    TCCT

    Written by Trimi Clinical Content Team

    Medical Writers & Healthcare Professionals

    Our clinical content team includes registered nurses, pharmacists, and medical writers who specialize in translating complex medical information into clear, actionable guidance for patients.

    Medically reviewed by Dr. Michael Rodriguez, MD, FACP, Board Certified in Internal Medicine

    What real Trimi patients say

    Verbatim quotes from Trimi's Facebook and Reddit community reviews. First name and last initial preserved per editorial policy.

    Just recieved my order today. I placed order Monday afternoon and arrived this afternoon. Everything packaged great, clear instructions to follow. The customer service was excellent. I have tried other companies, but this is the most affordable by far. I am almost at my goal weight.

    Outcome: Next-day arrival; most affordable tried; near goal weight

    - Raquel R.Facebook
    21 lbs down in 6 weeks! So happy I started with you guys!

    Outcome: 21 lbs lost in 6 weeks

    - Robyn Lynn CurtisFacebook

    Editorial Standards

    Trimi publishes patient education using a medical-review workflow, source-based claim checks, and dated updates for fast-changing pricing, access, and safety topics.

    Review our Editorial Policy and Medical Review Policy for more details about sourcing, updates, and reviewer attribution.

    Scientific References

    1. Jastreboff AM, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2206038
    2. Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England Journal of Medicine.Read StudyDOI: 10.1056/NEJMoa2032183
    3. Eli Lilly and Company (2025). Zepbound (tirzepatide) prescribing information. U.S. Food and Drug Administration.Read Study
    4. The Endocrine Society (2024). Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism.Read Study

    Was this article helpful?

    Keep Reading

    What to expect in your first month on retatrutide: realistic weight loss expectations, side effects, appetite changes, and tips for maximizing early results during the dose titration phase.

    Can Weight Loss Start After the First Month. Read the full clinician-reviewed Trimi guide, practical guidance plus Trimi's $99/mo compounded GLP-1 alternative for context.

    Buy compounded semaglutide online in Texas for $99/month. Learn about Texas telehealth laws, compounding pharmacy access, and how to start affordable GLP-1 weight loss treatment.

    Comprehensive comparison of retatrutide (triple agonist) vs tirzepatide (dual agonist). Compare weight loss results, mechanisms, timelines, and whether waiting for the next-generation drug makes sense

    Start your GLP-1 journey, from $99/mo

    Get Started